Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.68 |
| ▸ | TACR1 | P25103 | 7/20 | 0.49 |
| ▸ | F11 | P03951 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16676584 | 0.89 | UBASH3B (0.72) | UBASH3BTACR1F11MAPTPPARG | |
| SCHEMBL16676557 | 0.87 | UBASH3B (0.72) | UBASH3BTACR1F11MAPTPPARG | |
| SCHEMBL29868847 | 0.87 | UBASH3B (0.74) | UBASH3BTACR1F11MAPTPPARG | |
| SCHEMBL16666864 | 0.87 | UBASH3B (0.74) | UBASH3BTACR1F11MAPTPPARG | |
| SCHEMBL16676563 | 0.86 | UBASH3B (0.72) | UBASH3BTACR1F11PPARGKDM4E | |
| SCHEMBL29868810 | 0.86 | UBASH3B (0.72) | UBASH3BTACR1F11PPARGKDM4E | |
| SCHEMBL16667576 | 0.85 | UBASH3B (0.71) | UBASH3BTACR1F11PPARGKDM4E | |
| SCHEMBL16666706 | 0.85 | UBASH3B (0.68) | UBASH3BTACR1F11MAPTPPARG | |
| SCHEMBL23280196 | 0.84 | UBASH3B (0.70) | UBASH3BTACR1F11PPARGKDM4E | |
| SCHEMBL16666374 | 0.84 | UBASH3B (0.70) | UBASH3BTACR1F11PPARGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | claimed |
| EP-2865669-A1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2015-04-29 | — | — | EP | claimed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| EP-2865669-A1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2015-04-29 | — | — | EP | disclosed |
| EP-2865669-A1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2015-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | REV1, GRPR, SI | UBASH3B 2690/4885TACR1 2155/4885F11 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.